Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Serogroup B Meningococcal Meningitis

Drug Information

Target Indication

Serogroup B Meningococcal Meningitis

Clinical Trial

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Influenza

Heart Transplantation

Non-alcoholic Fatty Liver Disease (NAFLD)

Meningococcal Meningitis

Axial Spondyloarthritis